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Objective: Early-onset pre-eclampsia is primarily associated with placental dysfunction, whereas late-
onset pre-eclampsia is deﬁned as a maternal constitutional disorder. As a protein cosynthesized with
vasopressin, copeptin is a potential marker of metabolic syndrome and insulin resistance, which shares
similar risk factors with pre-eclampsia. The aim of this study was to investigate the copeptin levels in
patients with early-onset and late-onset pre-eclampsia.
Materials and methods: A total of 80 pregnant women receiving antenatal and obstetric care were
recruited. The patients were subdivided into four groups: Early-onset pre-eclampsia (n ¼ 20), late-onset
pre-eclampsia (n ¼ 20), and two control groups of similar gestational ages for both pre-eclamptic groups
(n ¼ 20 in each group). The maternal serum copeptin levels were measured using an enzyme-linked
immunosorbent assay.
Results: The mean copeptin levels were 0.92 ± 0.57 ng/mL and 1.65 ± 0.95 ng/mL in the early-onset and
late-onset pre-eclampsia groups, respectively. These values were higher compared with the control
groups (0.54 ± 0.25 ng/mL and 1.15 ± 0.94 ng/mL, respectively). However, the difference was only sta-
tistically signiﬁcant in the early-onset pre-eclampsia group (p ¼ 0.011). Copeptin levels were associated
only with gestational age and systolicediastolic blood pressure.
Conclusion: Our results suggest that copeptin levels might be useful in the evaluation of the severity of
pre-eclampsia. However, copeptin might be involved in early- rather than late-onset pre-eclampsia.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Pre-eclampsia is a multisystem disease of pregnancy, charac-
terized by new-onset hypertension and proteinuria, which de-
velops after 20 weeks of gestation in previously normotensive
women, complicating 3e5% of all pregnancies [1]. Although the
exact cause of pre-eclampsia remains unknown, this disease is
characterized by inadequate placentation, oxidative stress,
inﬂammation, and widespread endothelial dysfunction [2]. Pre-
eclampsia can be classiﬁed as early onset and late onset,and Gynecology, Cerrahpasa
pasa, Istanbul 34098, Turkey.
.
bstetrics & Gynecology. Publishedaccording to the development of symptoms before or after 34
weeks of pregnancy, respectively [3,4]. Early-onset pre-eclampsia
associated with placental dysfunction is markedly severe,
frequently leading to deliveries of growth-retarded premature ba-
bies or poor outcomes for mothers [5].
Women affected with pre-eclampsia have signiﬁcantly
increased risks of metabolic and cardiovascular diseases following
pregnancy [6,7]. Pre-eclampsia, metabolic syndrome, and cardio-
vascular diseases share the same risk factors, including obesity,
hypertension, dyslipidemia, hypercoagulability, and insulin resis-
tance, and these conditions are characterized by endothelial
dysfunction [8e10]. Recently, the activation of the stress-mediated
hypothalamicepituitaryeadrenal (HPA) axis, regulated through
copeptin, was implicated in the pathophysiology of metabolicby Elsevier Taiwan LLC. All rights reserved.
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hormone and copeptin-regulated stress-mediated HPA axis acti-
vation are involved in the endocrine stress response [12e14].
Copeptin is superior to cortisol in the determination of the stress
level, because cortisol has a strong circadian rhythm, and the
measurement of cortisol as a free hormone in serum remains
challenging [15].
Zulﬁkaroglu et al [16] reported that increased maternal levels of
copeptin might be involved in the pathogenesis of pre-eclampsia,
and copeptin might be a clinically useful biomarker for the
assessment of disease severity in early-onset pre-eclampsia. Simi-
larly, as an indicator of inadequate placentation in pre-eclampsia,
copeptin levels have been associated with abnormal uterine and
umbilical artery Doppler velocimetry values. Inadequate placenta-
tion is primarily associated with early-onset rather than late-onset
pre-eclampsia, whereas late-onset pre-eclampsia results from an
underlying maternal constitutional disorder. However, the out-
comes of late-onset pre-eclampsia resemble those of normal
pregnancies compared with early-onset pre-eclampsia. Therefore,
we hypothesized that copeptinmight be an important biomarker of
early- rather than late-onset pre-eclampsia.
Copeptin, a 39-amino acid glycopeptide, is cosynthesized in the
hypothalamus with vasopressin, which is also an antidiuretic hor-
mone. Copeptin can be used as an indicator of serum vasopressin
levels, because the levels of this hormone in serum are more stable
in plasma and serum compared with vasopressin [17]. In addition
to reﬂecting individual stress levels, vasopressin also has hemo-
dynamic and osmoregulatory effects. Interestingly, copeptin has
been shown to act identically with vasopressin during the course of
disorders of the osmoregulatory system, and copeptin levels have
been directly correlated with the plasma vasopressin levels in both
healthy volunteers and critically ill patients [18]. In addition,
copeptin levels have been demonstrated as independent predictors
of survival in patients suffering from hemorrhagic and septic shock
and have shown prognostic implications in diseases other than
infections [19].
In this study, we evaluated the copeptin levels in normal preg-
nancy and pregnancies complicated by early-onset and late-onset
pre-eclampsia. We also investigated the association between
maternal serum copeptin levels and umbilical and uterine artery
Doppler velocimetry values in pre-eclamptic patients.
Materials and methods
A total of 80 pregnant women, comprising 40 women with
normal pregnancies and 40 women diagnosed with pre-eclampsia,
receiving antenatal and obstetric care at the Department of Ob-
stetrics and Gynecology, Istanbul University Cerrahpasa Faculty of
Medicine Hospital (Istanbul, Turkey), from May 2012 to July 2012,
were recruited for this case-control study. Pre-eclampsia was
deﬁned according to the criteria of the American College of Ob-
stetrics and Gynecology (ACOG practice bulletin) [20]. Pre-
eclampsia was determined through increased blood pressure
(>140/90 mmHg) occurring in a pregnant woman after 20 weeks of
amenorrhea, accompanied by proteinuria (0.3 g/24 h), as deﬁned
according to the National High Blood Pressure Education Program
Working Group on High Blood Pressure in Pregnancy.
The patients with pre-eclampsia were divided into two groups
as follows: 20 patients diagnosed before 34 weeks of gestation
were deﬁned as having “early-onset pre-eclampsia,” and those
diagnosed and delivered at 34 weeks of gestation or later were
deﬁned as having “late-onset pre-eclampsia.” For each patient with
pre-eclampsia, one control woman was randomly matched ac-
cording to weeks of gestation among normotensive patients with
uncomplicated pregnancies who delivered healthy babies weighing>2500 g at term. This group was divided into two subgroups based
on the gestational weeks (early and late control groups). The early
control group comprised 20 healthy pregnant women recruited
during a routine visit to the antenatal clinic at 24e34 gestational
weeks; only those women whose pregnancies continued normally
remained in this group. The late control group comprised 20
healthy pregnant women recruited during a routine visit to the
antenatal clinic following the completion of 34 gestational weeks.
Therefore, the control groups were appropriately structured for
statistical evaluation in terms of gestational weeks for both early-
onset and late-onset pre-eclamptic patient groups. The mean
ages, gestational weeks, and body mass index (BMI) were evalu-
ated. The BMI was calculated using the following formula: weight
(kg)/height (m)2.
The following exclusion criteria were used: multiple pregnan-
cies, pregestational or gestational diabetes mellitus, smoking,
chronic hypertension, polyhydramnios, prior renal diseases, and
evidence of acute or chronic inﬂammation. The diagnosis of preg-
nancy was based on a positive serum beta-human chorionic
gonadotropin test and the presence of fetal heart beat in the uterine
cavity on ultrasonographic evaluation. The gestational ages were
evaluated according to the last menstrual period and conﬁrmed
through ultrasound performed until 14 gestational weeks, based on
the crown rump length values of the embryos.
Blood samples were collected from each participant before
administration of any medication and before any medical or sur-
gical intervention. None of the patients was in labor at the time of
sampling. The serum was separated by centrifuging the samples at
4000g for 10 minutes and freezing at 80C for later analysis. The
serum copeptin concentrations were measured in duplicate using a
competitive enzyme immunoassay (Catalog No. EK-065-32
copeptin-human EIA kit: Phoenix Pharmaceuticals, Inc., CA, USA).
The assay sensitivity was 0.12 ng/mL, and the interassay and intra-
assay calculation values were 5e10% and <15%, respectively.
The umbilical artery and uterine artery blood-ﬂow velocity
values were obtained using transabdominal color and pulsed
Doppler velocimetry measurements of the uterine and umbilical
arteries, performed by the same physician (A.T.) for all study pa-
tients. Voluson 730 Pro ultrasound machines (GE Healthcare, UK),
equipped with pulsed and color Doppler technologies, were used,
and uterine and umbilical artery Doppler velocimetry values were
measured. Informed consent was obtained from all women, and the
study protocol was approved through the Human Ethics Committee
of Istanbul University.
All statistical analyses were performed using the Statistical Pack-
age for the Social Sciences (SPSS) software version 18.0, SPSS Inc.,
Chicago, IL, USA. The data are presented as the arithmetical means,
and the standard deviationswere calculated for each group. Student t
test was used for comparison of the parametric variables, and chi-
square test was used for comparison of the nonparametric vari-
ables. The relationship between a particular biochemical parameter
and the stage or gradewas evaluatedusing Pearson correlation test. A
p value < 0.05 was considered statistically signiﬁcant.
Results
The clinical characteristics, uterine and umbilical artery Doppler
velocimetry ﬁndings, and mean maternal serum copeptin levels of
the subgroups (early-onset pre-eclampsia, late-onset pre-
eclampsia, and 2 control groups) are summarized in Table 1. Pre-
eclamptic patients in both early-onset and late-onset groups were
compared with their gestational age-matched controls.
No statistical differences were observed between the patients
with early-onset pre-eclampsia and their respective controls in
terms of mean maternal ages, BMI values, mean gestational ages at
Table 1
Baseline characteristics of the patients.
Early-onset controls
(n ¼ 20)
Early-onset pre-eclampsia
(n ¼ 20)
p Late-onset controls
(n ¼ 20)
Late-onset pre-eclampsia
(n ¼ 20)
p
Maternal age (y) 30.4 ± 3.44 29.1 ± 6.1 NS 30.9 ± 3.4 31.1 ± 4.1 NS
Nulliparity, n (%) 3 (15) 9 (45) 0.01 3 (15) 5 (25) NS
Previous pre-eclampsia, n (%) 0 (0) 5 (25) 0.03 0 (0) 0 (0) NS
Gestational age at sampling (d) 28.65 ± 0.48 28.8 ± 2.0 NS 36.0 ± 0.9 35.8 ± 1.2 NS
BMI (kg/m2) 29.8 ± 1.9 30.2 ± 2.3 NS 29.4 ± 0.6 29.5 ± 4.5 NS
SBP (mmHg) 104 ± 7.5 160 ± 20.2 0.001 110.5 ± 8.5 153.5 ± 23.9 0.001
DBP (mmHg) 67.5 ± 7.1 105.5 ± 13.9 0.001 71.6 ± 76 101.3 ± 17.1 0.001
Birth weight (g) 3184 ± 421 1398 ± 357 0.001 3059 ± 328 2288 ± 740 0.001
IUGR, n (%) 0 (0) 15 (75) 0.001 0 (0) 11 (55) 0.001
Uterine artery PI 0.88 ± 0.10 0.99 ± 0.18 0.029 0.82 ± 0.11 1.00 ± 0.19 0.003
Uterine artery RI 0.54 ± 0.07 0.56 ± 0.09 NS 0.51 ± 0.06 0.55 ± 0.83 NS
Umbilical artery PI 0.86 ± 0.10 1.04 ± 0.24 0.004 0.80 ± 0.12 1.13 ± 0.35 0.001
Umbilical artery RI 0.56 ± 037 0.58 ± 0.06 NS 0.55 ± 0.05 0.67 ± 0.08 NS
Copeptin (ng/mL) 0.54 ± 0.25 0.92 ± 0.57 0.011 1.15 ± 0.94 1.65 ± 0.95 NS
All values are presented as means ± standard deviation, unless otherwise indicated differently.
*p < 0.05 is considered statistically signiﬁcant.
BMI ¼ body mass index; DBP ¼ diastolic blood pressure; IUGR ¼ intrauterine growth restriction; NS ¼ not signiﬁcant; PI ¼ pulsatility index; RI ¼ resistivity index;
SBP ¼ systolic blood pressure.
Figure 1. Serum copeptin concentrations in women with pre-eclampsia and normal
controls.
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dex (RI) values. The percentage of nulliparity was higher in the pre-
eclampsia group (p ¼ 0.01), and there were ﬁve patients with a
history of previous pre-eclampsia in the pre-eclampsia group,
whereas the control group had none (p¼ 0.01). The birth weights of
the newborns were signiﬁcantly different between the groups
(p ¼ 0.001), and 75% of the patients with pre-eclampsia delivered
babies with intrauterine growth retardation (IUGR), whereas no
babies with IUGR were delivered in the control group (p ¼ 0.001).
The mean systolic and diastolic blood pressures and both umbilical
and uterine artery Doppler velocimetry pulsatility index (PI) values
were signiﬁcantly higher in the pre-eclampsia group (p ¼ 0.001,
p ¼ 0.001, p ¼ 0.029, and p ¼ 0.004, respectively).
No statistically signiﬁcant differences were observed in patients
with late-onset pre-eclampsia when compared with their control
groups in terms of mean maternal ages, percentage of nulliparity,
number of patients with previous pre-eclampsia diagnosis, BMI
values, uterine and umbilical artery RI values, and gestational age at
sampling time. The birth weights of the newborns were signiﬁ-
cantly different between the groups (p ¼ 0.001). Approximately
55% of the patients with pre-eclampsia delivered babies with IUGR;
however, no babies with IUGR were delivered in the control group
(p ¼ 0.001). The mean systolic and diastolic blood pressures and
both umbilical and uterine artery Doppler velocimetry PI values
were signiﬁcantly higher in the pre-eclampsia group (p ¼ 0.001,
p ¼ 0.001, p ¼ 0.003, and p ¼ 0.001, respectively).
The mean maternal serum copeptin levels were higher in both
early-onset and late-onset pre-eclamptic patients compared with
their control groups (Figure 1). However, this difference was only
statistically signiﬁcant in patients diagnosed with early-onset pre-
eclampsia (p ¼ 0.011).
As shown in Table 2, the maternal serum copeptin levels did not
correlate with the maternal BMI values, birth weights of the new-
borns, and the umbilical and uterine artery PI and RI Doppler
velocimetry values. However, there was a correlation between
maternal serum copeptin levels, gestational age, and systolic and
diastolic blood pressures (p ¼ 0.001, p ¼ 0.047, and p ¼ 0.038,
respectively).
Discussion
The major ﬁndings of this study are as follows: (1) maternal
serum copeptin levels were markedly increased in patients diag-
nosed with pre-eclampsia in the third trimester compared withwomen with normal, ongoing pregnancies of similar gestational
age. The increase of copeptin levels in patients with early-onset
pre-eclampsia was statistically signiﬁcant compared with the
control group. However, a similar difference in patients with late-
onset pre-eclampsia was not statistically signiﬁcant. (2) Although
maternal serum copeptin levels were positively correlated with
gestational age, and systolic and diastolic blood pressure, the levels
did not correlate with maternal age, BMI, birth weight, and uterine
and umbilical artery Doppler values in both early-onset and late-
onset pre-eclampsia.
Early-onset pre-eclampsia is primarily considered a fetal disor-
der, typically associated with placental dysfunction, a reduction in
placental volume, intrauterine growth restriction, abnormal uter-
ine and umbilical artery Doppler evaluation, low birth weight,
multiorgan dysfunction, perinatal death, and adverse maternal and
neonatal outcomes [21,22]. By contrast, late-onset pre-eclampsia is
considered a maternal disorder, resulting from an underlying
maternal constitutional disorder, associated with a normal
placenta, larger placental volume, normal fetal growth, normal
Table 2
Correlations between serum copeptin levels and all the other parameters assessed in
all groups.
Copeptin
r p
Maternal age 0.129 0.253
BMI 0.141 0.212
Gestational week 0.401 0.001*
Birth weight 0.134 0.237
SBP 0.223 0.047*
DBP 0.242 0.038*
Umbilical artery PI 0.110 0.925
Umbilical artery RI 0.161 0.165
Uterine artery PI 0.009 0.937
Uterine artery RI 0.630 0.537
*p < 0.05 is considered statistically signiﬁcant.
BMI ¼ body mass index; DBP ¼ diastolic blood pressure; PI ¼ pulsatility index;
r ¼ correlation coefﬁcient; RI ¼ resistivity index; SBP ¼ systolic blood pressure.
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weight, and more favorable maternal and neonatal outcomes
[21,23e25].
Zulﬁkaroglu et al [16] documented the elevation of serum
copeptin levels in patients diagnosed with pre-eclampsia. Consis-
tent with these data, the serum copeptin levels were higher in both
early-onset and late-onset pre-eclampsia compared with the con-
trol groups in this study. The elevation of the serum copeptin levels
in pre-eclamptic patients might reﬂect the fact that arginine
vasopressin directly stimulates cortisol release in humans through
the activation of V1a receptors on adrenal cortex cells [26], resulting
in salt and water retention, causing pre-eclampsia. In addition,
arginine vasopressin activates the receptors on the chromafﬁn cells
in the adrenal medulla, leading to an increase in the vasoconstric-
tive epinephrine levels, which might subsequently contribute to
hypertension in pre-eclampsia [27].
The pre-eclamptic patients included in the Zulﬁkaroglu et al [16]
study were compatible with the diagnosis criteria of early-onset
pre-eclampsia. However, in our study, the elevation of serum
copeptin levels was only statistically signiﬁcant in the early-onset
pre-eclampsia group. Because the copeptin levels have been asso-
ciated with individual stress levels [18], and early-onset pre-
eclampsia is presumed to be a considerably severe condition
compared with late-onset pre-eclampsia, this signiﬁcant difference
in the copeptin levels in early-onset pre-eclampsia might reﬂect a
relatively stressful condition.
Zulﬁkaroglu et al [16] concluded that the increase in serum
copeptin levels was correlated with the severity of the disease and
abnormal uterine and umbilical Doppler velocimetry results. In our
study, we observed no correlation between maternal serum
copeptin and uterine and umbilical artery Doppler velocimetry
values in patients with pre-eclampsia. This ﬁnding is in contrast to
the results reported by Zulﬁkaroglu et al [16]. Therefore, we suggest
that the relation between copeptin and impaired uteroplacental
perfusion remains controversial. Moreover, in this study, regardless
of the onset of the disease, maternal serum copeptin levels were
positively associated with elevated systolic and diastolic blood
pressure, considered as diagnostic criteria for pre-eclampsia and a
poor prognostic factor. This correlation might reﬂect the activation
of the receptors on chromafﬁn cells in the adrenal medulla, as
described earlier [27].
Previous studies have reported that normal human pregnancy
dramatically affects the HPA axis, in which copeptin has been
shown to act as a regulative factor [28,29]. Increased placental es-
trogen production stimulates hepatic corticosteroid-binding glob-
ulin production [30,31], eventually depleting the levels of freecortisol, and thereby activating the HPA axis and increasing serum
levels of free cortisol [32e35]. In this study, the maternal serum
copeptin levels were also positively associated with gestational age
in all groups, presumably reﬂecting increased individual stress
levels during pregnancy. This increase in serum copeptin levels was
also exaggerated in patients diagnosed with both early-onset and
late-onset pre-eclampsia, likely reﬂecting the extra chronic phys-
ical stress caused by the disease itself. The small patient population
contributed to the limitations of this study. Future studies with
larger populations are needed to obtain a relatively elaborate
deﬁnition of copeptin secretion, metabolism, and action in patients
with pre-eclampsia.
In conclusion, early-onset pre-eclampsia has been associated
with impaired maternal and fetal outcomes compared with late-
onset pre-eclampsia. The results obtained in this study have
shown that serum copeptin levels are positively correlated with
early-onset pre-eclampsia, potentially reﬂecting the presence of
relatively increased physiological stress. In addition, the serum
copeptin levels were associated with elevated systolic and diastolic
blood pressure. Moreover, these results have revealed a positive
correlation between maternal serum copeptin levels and gesta-
tional age, suggesting a gradual increase in HPA axis activation.Conﬂicts of interest
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